ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study (EVINEC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02113800
Recruitment Status : Recruiting
First Posted : April 15, 2014
Last Update Posted : January 23, 2018
Sponsor:
Collaborators:
Assign Data Management and Biostatistics GmbH
Novartis Pharmaceuticals
Information provided by (Responsible Party):
AIO-Studien-gGmbH

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : November 2018
  Estimated Study Completion Date : February 2019